RxDoctor Payments Data

Salil Gupta, MD

Nephrology · North Syracuse, NYNPI 1316041551

Payments from drug & device makers

$2,166in general payments, 2019–2025

Across 77 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$297
  • Bayer$277
  • GSK$251
  • Aurinia Pharma U.S., Inc.$219
  • Otsuka America Pharmaceutical, Inc.$194
  • Medtronic$156
  • plus $771 from 14 others

What the payments were for

  • Food & beverage$1,96691%
  • Education$2019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,166 in reported general payments places this provider in the 65th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$468,353
Medicare patients
895
Services billed
42,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide57$176,719
JardianceEmpagliflozin97$78,911
JanuviaSitagliptin Phosphate61$61,823
FarxigaDapagliflozin Propanediol71$55,940
OzempicSemaglutide30$43,628
TrulicityDulaglutide29$40,445
Tresiba Flextouch U-200Insulin Degludec15$39,445
MounjaroTirzepatide36$38,858
EliquisApixaban31$35,604
Sevelamer Carbonate115$25,222
KerendiaFinerenone22$24,185
RetacritEpoetin Alfa-Epbx14$22,981
Tresiba Flextouch U-100Insulin Degludec12$14,404
EntrestoSacubitril/Valsartan15$13,601
Novolog FlexpenInsulin Aspart47$11,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$34$176,71957 claims
AstraZenecaFarxiga$135$55,94071 claims
Novo NordiskOzempic$16$43,62830 claims
BayerKerendia$277$24,18522 claims
NovartisEntresto$23$13,60115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 nephrology providers in New York.

Other nephrology in North Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →